Latest stories on GLMD
Galmed Unveils High-Exposure Orally Dispersible Aramchol Formulation for Parkinson’s Disease
TipRanks63 · neutralproduct/pr
Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)
InvestorsHub63 · neutralproduct/pr
Galmed Pharmaceuticals Reports Wider Q1 2026 Loss Amid Higher R&D Spending
TipRanks34 · bearishearnings
Galmed Pharmaceuticals Closes Amended All-Cash Colospan Acquisition With Earnout Structure
TipRanks63 · neutralm&a
Galmed to acquire Colospan in $4.5M deal; shares down
Seeking Alpha54 · neutralm&a
Galmed Pharmaceuticals to Acquire Colospan and Commit $6 Million to European Expansion
TipRanks63 · neutralm&a
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
PR Newswire68 · bullishm&a
Galmed and Tissue Dynamics Reveal New Metabolic Target for Cardiac Fibrosis With Aramchol Combo
TipRanks63 · neutralproduct/pr